Literature DB >> 16351644

Genetic and clinical heterogeneity of ferroportin disease.

L Cremonesi1, Laura Cemonesi, Gian Luca Forni, Nadia Soriani, Martina Lamagna, Isabella Fermo, Filomena Daraio, Anna Galli, Daniela Pietra, Luca Malcovati, Maurizio Ferrari, Clara Camaschella, Mario Cazzola.   

Abstract

Ferroportin is encoded by the SLC40A1 gene and mediates iron export from cells by interacting with hepcidin. SLC40A1 gene mutations are associated with an autosomal type of genetic iron overload described as haemochromatosis type 4, or HFE4 (Online Mendelian Inheritance in Man number 606069), or ferroportin disease. We report three families with this condition caused by novel SLC40A1 mutations. Denaturing high-performance liquid chromatography was employed to scan for the SLC40A1 gene. A D181V (A846T) mutation in exon 6 of the ferroportin gene was detected in the affected members of an Italian family and shown to have a de novo origin in a maternal germinal line. This mutation was associated with both parenchymal and reticuloendothelial iron overload in the liver, and with reduced urinary hepcidin excretion. A G80V (G543T) mutation in exon 3 was found in the affected members of an Italian family with autosomal hyperferritinaemia,. Finally, a G267D (G1104A) mutation was identified in exon 7 in a family of Chinese descent whose members presented with isolated hyperferritinaemia. Ferroportin disease represents a protean genetic condition in which the different SLC40A1 mutations appear to be responsible for phenotypic variability. This condition should be considered not only in families with autosomal iron overload or hyperferritinaemia, but also in cases of unexplained hyperferritinaemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16351644     DOI: 10.1111/j.1365-2141.2005.05815.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders.

Authors:  Yoshibumi Kaneko; Hiroaki Miyajima; Alberto Piperno; Naohisa Tomosugi; Hisao Hayashi; Natsuko Morotomi; Ken-ichi Tsuchida; Takaaki Ikeda; Akihisa Ishikawa; Yusuke Ota; Shinya Wakusawa; Kentaro Yoshioka; Satoshi Kono; Sara Pelucchi; Ai Hattori; Yasuaki Tatsumi; Toshihide Okada; Masakazu Yamagishi
Journal:  J Gastroenterol       Date:  2010-06-09       Impact factor: 7.527

2.  Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency.

Authors:  Janine Meienberg; Marianne Rohrbach; Stefan Neuenschwander; Katharina Spanaus; Cecilia Giunta; Sira Alonso; Eliane Arnold; Caroline Henggeler; Stephan Regenass; Andrea Patrignani; Silvia Azzarello-Burri; Bernhard Steiner; Anders O H Nygren; Thierry Carrel; Beat Steinmann; Gábor Mátyás
Journal:  Eur J Hum Genet       Date:  2010-07-21       Impact factor: 4.246

3.  Tumor necrosis factor-alpha promoter variants and iron phenotypes in 785 hemochromatosis and iron overload screening (HEIRS) study participants.

Authors:  Ronald T Acton; James C Barton; Catherine Leiendecker-Foster; Christopher Zaun; Christine E McLaren; John H Eckfeldt
Journal:  Blood Cells Mol Dis       Date:  2010-02-23       Impact factor: 3.039

Review 4.  The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.

Authors:  Hiroshi Kawabata
Journal:  Int J Hematol       Date:  2017-11-13       Impact factor: 2.490

5.  Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination.

Authors:  Bo Qiao; Priscilla Sugianto; Eileen Fung; Alejandro Del-Castillo-Rueda; Maria-Josefa Moran-Jimenez; Tomas Ganz; Elizabeta Nemeth
Journal:  Cell Metab       Date:  2012-06-06       Impact factor: 27.287

6.  Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin.

Authors:  Sergei Nekhai; Min Xu; Altreisha Foster; Ishmael Kasvosve; Sharmin Diaz; Roberto F Machado; Oswaldo L Castro; Gregory J Kato; James G Taylor; Victor R Gordeuk
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

7.  Non-HFE hemochromatosis.

Authors:  Paulo Caleb Júnior de Lima Santos; Carla Luana Dinardo; Rodolfo Delfini Cançado; Isolmar Tadeu Schettert; José Eduardo Krieger; Alexandre Costa Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 8.  Physiology of iron metabolism.

Authors:  Sophie Waldvogel-Abramowski; Gérard Waeber; Christoph Gassner; Andreas Buser; Beat M Frey; Bernard Favrat; Jean-Daniel Tissot
Journal:  Transfus Med Hemother       Date:  2014-05-12       Impact factor: 3.747

9.  Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening.

Authors:  James C Barton; Ronald T Acton; Catherine Leiendecker-Foster; Laura Lovato; Paul C Adams; John H Eckfeldt; Christine E McLaren; Jacob A Reiss; Gordon D McLaren; David M Reboussin; Victor R Gordeuk; Mark R Speechley; Richard D Press; Fitzroy W Dawkins
Journal:  Am J Hematol       Date:  2008-02       Impact factor: 10.047

Review 10.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.